EHA 2021 CML updates

For Chronic Myeloid Leukemia Patient Group Advocates

CML Advocates Network, EHA 2021
 

26th European Hematology Association Congress
Highlights from sessions dedicated to Chronic Myeloid Leukemia

Only two weeks left to start the European Hematology Association Congress 2021 from June 9 to 17 and get informed about the highlight state-of-the-art clinical practice, recent advances, new data and views from different stakeholders as well as international organizations.
 
Once again, we will be attending this key meeting for the CML patient advocacy community that will be held online due to the impact of COVID-19 for the second time in its history, and sharing with you the information on our social media channels and website.
 
This is an excellent opportunity to explore the newest developments in CML and beyond and new evidence-based approaches to diagnosis and treatment. Moreover, this year the European Hematology Association is introducing several new session types at #EHA2021 as on-demand Guidelines Sessions or live Thematic Debates.
 
Check out the CML featured sessions we have summarized for you:

EHA-Patient Joint Symposium – EHA2021 Virtual

 

Part 1: Wednesday, June 9, 13:00-16:00 CET
 
SESSION I: Coming to haematology soon: Diagnostic regulations – Threat or opportunity for innovative diagnostics?
 
SESSION II: Affordable access to orphan medicines.
 
Part 2: Friday, June 11, 13:00-14:00 CET
 
SESSION III: Lessons from COVID.
 
Part 3: Saturday, June 12, 10:00-12:45 CET
 
SESSION IV: Personalized Medicine Trials.
 
SESSION V: Reducing Bureaucracy in Clinical Trials.
 

CML Education Session 

Stem cells targeting in CML. 
On demand from 11 June 2021 09:00 AM CET.

Chair: O Hantschel (Germany)

  • CML Biology. M Deininger (United States)
  • Immune cell contexture and response. S Mustjoki (Finland)
  • Treatment free remission in CML. FX Mahon (France)
Live Q&A Panel Discussion.
16 June 2021 4:00 PM – 4:45 PM CET, Virtual room 1.

Plenary Sessions 

Plenary Session II.
2 June 2021 3:15 PM – 3:45 PM CET

p202-3 Physiopathology of coagulopathy in hematological malignancies and in COVID-19. Dr. Marcel Levi, The Netherlands.

Joint Symposia

EHA-CSH Joint Symposium: COVID-19 in hematology 
12 June 2021 10:00 AM – 11:00 AM CET. Virtual room 1.

Chairs: J Gribben (United Kingdom) & D Wu (China)

  • Abnormalities in thrombosis and hemostasis in patients with COVID-19. H Yu (China).

Scientific Working Group Sessions

ELN-EHA SWG for CML: Chronic myeloid leukemia. 
On demand from 11 June 2021. 09:00 AM CET

Chair: R Hehlmann (Germany)

  • CML and COVID-19 - What do we know in 2021? D Rea (France)
  • The new ELN recommendations for treating CML. A Hochhaus (Germany)
  • CML and BCR-ABL monitoring: The poster child for molecular monitoring of hematologic neoplasms. N Cross (United Kingdom)
  • The CML genomics/HARMONY PLUS project. S Branford (Australia) 
Live Q&A Panel Discussion.
16 June 2021 11:00 AM – 11:45 AM CET. Virtual room 1.

 

Telemedicine in vulnerable older adults with hematological malignancies in the time of COVID-19. SWG: Aging and hematology.
On demand from 11 June 2021. 09:00 AM CET

Chair: V Goede (Germany)

  • Remote telehealth assessment and monitoring in older and vulnerable cancer patients. R Stauder (Austria)
  • Bridging hospital care closer to older adults with hematological malignancies amidst COVID-19 pandemic in Madrid: The Spanish experience. R Cordoba (Spain)
  • Outcome of older adults with hematological malignancies in Brescia: The Italian experience. G Rossi (Italy)
Live Q&A Panel Discussion.
13 June 2021 3:00 PM – 3:45 PM CET. Virtual room 2.

 

The critically ill patient during the pandemic. SWG: Infections in hematology.
On demand from 11 June 2021. 09:00 AM CET

Chair: O Cornely (Germany)

  • Pharmacokinetic considerations of anti-infective drugs in the ICU: Drug-drug interactions, ECMO, Renal Replacement Therapy. RE Lewis (Italy)
  • Fungal superinfections complicating severe COVID-19 in the ICU. M Hoenigl (Austria)
  • ICU admission of hematological patients during the pandemic: Who to admit and what’s the prognosis?. P Koehler (Germany)
  • EPICOVIDEHA survey: COVID-19 infections in patients with hematological malignancies – Results from EHA-IDWP registry. L Pagano (Italy)
Live Q&A Panel Discussion.
13 June 2021 1:00 PM – 1:45 PM CET. Virtual room 2.

CML Thematic Day

Guidelines Sessions.

The Guidelines Sessions are a New Session Format introduced at EHA2021. The aim is to disseminate good practices and knowledge for diagnosis and treatment of hematologic diseases based on EHA produced or endorsed guidelines.

Chronic Myelomonocytic Leukemias: EHA Guidelines on Diagnosis and Treatment in Adults. 
9:00 AM – 9:45 AM CET, Virtual room 1.

 
Thematic Debates.

Thematic Debates are part of the New Session formats introduced at EHA2021. These are lively and interactive debates, where 2 or more speakers will present opposing positions followed by a discussion afterwards.

Clonal hematopoesis and cardiovascular disease.
9:00 AM – 9:45 AM CET, Virtual room 2.

Pediatric hematology: Should children be treated differently than adults? 9:00 AM – 9:45 AM CET, Virtual room 3.
 

Live Q&A Panel Discussions on CML
 
 ELN-EHA SWG for CML. Live Panel Discussion
11:00 AM – 11:45 AM CET. Virtual room 1.

Oral Session: Population based studies in myeloid disorders. Live Panel Discussion 
1:00 PM – 1:45 PM CET. Virtual room 2.

Oral Session: Response, resistance and treatment-free remission in CML. Live Panel Discussion 
2:00 PM – 2:45 PM CET

Education Session. Live Panel Discussion 
4:00 PM – 4:45 PM CET, Virtual room 1.

Oral Sessions

Population based studies in myeloid disorders.
 
P411-1 (S155) THE LOSS OF LIFE EXPECTANCY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2018. Msc Carolien Maas, The Netherlands.
 
P411-2 (S156) ELTROMBOPAG FOR MYELODYSPLASTIC SYNDROMES OR CHRONICMYELOMONOCYTIC LEUKEMIA WITH NO EXCESS BLASTS AND THROMBOCYTOPENIA: A FRENCH MULTICENTER RETROSPECTIVE REAL-LIFE STUDY. Dr. Thibault Comont, France.
 
P411-4 (S158) IMPACT OF RUXOLITINIB ON SURVIVAL OF PATIENTS WITH MYELOFIBROSIS IN REAL WORLD – UPDATE OF ERNEST (EUROPEAN REGISTRY FOR MYELOPROLIFERATIVE NEOPLASMS) STUDY. Dr. Paola Guglielmelli, Italy.
 
P411-5 (S159) CLONAL HEMATOPOIESIS, ELEVATED BLOOD CELL COUNTS, AND DECREASED RENAL FUNCTION – A GENERAL POPULATION STUDY. Msc Morten Kranker Larsen, Denmark.
 
Live Q&A Panel Discussion.
16 June 2021 1:00 PM – 1:45 PM CET. Virtual room 2.
 
  
Response, resistance and treatment-free remission in CML
 
p410-1 (S150) LOSS OF G0/G1 SWITCH GENE 2 (G0S2) IN CML PROMOTES TKI RESISTANCE BY DEREGULATING THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN. Mayra Gonzalez, United States.

p410-2 (S151) MITOCHONDRIAL DNA MUTATIONS ARE ASSOCIATED WITH RESPONSE TO IMATINIBIN CHRONIC MYELOID LEUKAEMIA PATIENTS. Dr. Ilaria Stefania Pagani, Australia.

p410-3 (S152) FINAL ANALYSIS OF A PAN EUROPEAN STOP TYROSINE KINASE INHIBITOR TRIAL IN CHRONIC MYELOID LEUKEMIA : THE EURO-SKI STUDY. Prof. Dr. Susanne Saussele, Germany.

p410-4 (S153) OPTIC PRIMARY ANALYSIS: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB (PON). Dr. Jorge Cortes, United States.

p410-5 (S154) COVID-19 INFECTION IN CHRONIC MYELOID LEUKEMIA AFTER 1 YEAR OF THE PANDEMIC IN ITALY. A CAMPUS CML ANALYSIS. Dr. Massimo Breccia, Italy.
 

Live Q&A Panel Discussion.
16 June 2021 2:00 PM – 2:45 PM CET. Virtual room 2.

Posters

 
Our Abstract “Chronic Myeloid Leukemia Access to Tyrosine Kinase Inhibitors and Polymerase Chain Reaction Testing in Central and Eastern Europe and West Asia Region: A Patient Advocacy Perspective” has been selected by the European Hematology Association Scientific Program Committee for an e-poster presentation during the #EHA2021 Congress.
Check out this Poster and many others about Chronic myeloid leukemia – Biology & Translational Research, Clinical and Quality of life, palliative care, ethics and health economics.

Click here for more information
 

See you on our Social Media Channels with #EHA2021!